Patient Communication in Psoriasis Remission

This episode, titled ‘Patient Perspectives in Psoriasis Remission,’ features panelists exploring the complexity of defining remission in psoriasis by examining the alignment between clinician-defined targets and patient expectations. While advances in biologic therapies have made complete skin clearance an increasingly achievable goal, the faculty highlight that remission extends beyond visible disease. The discussion emphasizes that even minimal residual disease or associated symptoms can meaningfully impact a patient’s quality of life, underscoring the importance of a more holistic approach to care.

The expert dermatologists examine how treatment decisions have evolved from a primary focus on efficacy toward a more nuanced balance that includes comorbidities, such as psoriatic arthritis and cardiovascular risk, as well as treatment burden and patient preferences. As therapeutic options have improved, clinicians are now faced with more complex decisions, including how aggressively to pursue complete clearance and how to balance that goal with long-term safety, cost considerations, and the finite number of available treatment options.

They also address the role of patient-reported outcomes in defining remission, noting that measures such as itch, pain, and quality of life do not always correlate directly with clinical clearance. The panelists highlight the need for ongoing dialogue between clinicians and patients to ensure treatment goals reflect what matters most to the individual. This discussion reinforces that remission in psoriasis is not a one-size-fits-all concept, but rather a dynamic, patient-centered goal that requires thoughtful, individualized care.

In the next episode, ‘Understanding Biologic Therapies in Psoriasis,’ panelists will review the key differences between biologic classes in psoriasis and the importance of targeting specific inflammatory pathways. It highlights how advances in immunology have enabled individualized treatment approaches.